As of 3:59pm ET
| +0.12 / +1.81%|
The 2 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 22.50, with a high estimate of 25.00 and a low estimate of 20.00. The median estimate represents a +233.83% increase from the last price of 6.74.
The current consensus among 2 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.